Aim: The purpose of this study was to compare the immunohistochemical profile of cell cycle inhibitors of G1/S phase transition (p21, p53 and pRb), Ki-67 proliferation marker and DNA ploidy in male (MBC) and female breast cancer (FBC). Material and Methods: One hundred patients (50 non-consecutive cases of FBC and an equal number of MBC) were selected according to homogeneous features regarding age, histological type, tumour grading, nodal status and absence of neoadjuvant therapy. The expression of p21, p53, pRb and Ki-67 was assessed by immunohistochemistry, and DNA ploidy was analysed by flow cytometry. Correlations between variables were evaluated using the χ2 test. Results: The incidence of DNA aneuploid, p21-positive and p53-negative tumours was significantly higher in MBC than in FBC; pRb and Ki-67 revealed no statistically significant differ- ences between the two entities. In MBC, high tumour grade correlated with aneuploidy, Ki-67 and pRb positivity; ploidy and p53 were also associated. In FBC, only ploidy and grade showed a strong correlation. Conclusion: The significant dissimilarities regarding DNA ploidy, p21 and p53 in these quite homogeneous groups of FBC and MBC point to different genomic instability and to differences in cell cycle proliferative control, reinforcing the view of somewhat distinct tumour oncogenesis.

Keywords:
Male/female breast cancer, p21, p53, pRb, Ki-67, Ploidy
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.